Medicinal composition containing pimobendan and preparation method of medicinal composition

A technology of pimobendan and its composition, which is applied in the field of pimobendan-containing pharmaceutical composition and its preparation, can solve the problem of low solubility of pimobendan, achieve strong vasodilation and platelet aggregation, Improved solubility and good stability

Inactive Publication Date: 2017-05-31
QINGDAO AGRI UNIV
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] By searching relevant literature and patents, we can see that many preparations cannot solve the problem of low solubility of pimobendan

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing pimobendan and preparation method of medicinal composition
  • Medicinal composition containing pimobendan and preparation method of medicinal composition
  • Medicinal composition containing pimobendan and preparation method of medicinal composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037]

[0038]

[0039] Preparation:

[0040] a) uniformly mix pimobendan and anhydrous citric acid in a ratio of 1:20, and ultrafinely pulverize them in an ultrafine pulverizer to obtain a micronized mixture with a particle size of 200 mesh;

[0041] b) Other ingredients are passed through a 100-mesh sieve respectively, and set aside;

[0042] c) mix a) with cornstarch, microcrystalline cellulose, 75% low-substituted hydroxypropyl cellulose, and beef powder in equal increments;

[0043] d) adding an aqueous solution of hypromellose to c) to make a soft material;

[0044] e) Perform wet granulation of the prepared soft material, dry at 65°C until the moisture content of the granules is about 3%, and granulate;

[0045] f) Add 25% low-substituted hydroxypropyl cellulose to e), and mix well;

[0046] g) adding micropowder silica gel and magnesium stearate to f), and mixing uniformly;

[0047] h) Compressing the obtained g) into tablets.

Embodiment 2

[0049]

[0050] Preparation:

[0051] a) uniformly mix pimobendan and anhydrous citric acid in a ratio of 1:20, and ultrafinely pulverize them in an ultrafine pulverizer to obtain a micronized mixture with a particle size of 400 mesh;

[0052] b) Other ingredients are passed through a 100-mesh sieve respectively, and set aside;

[0053] c) mix a) with cornstarch, microcrystalline cellulose, 75% low-substituted hydroxypropyl cellulose, and beef powder in equal increments;

[0054] d) adding an aqueous solution of hypromellose to c) to make a soft material;

[0055] e) Perform wet granulation of the prepared soft material, dry at 65°C until the moisture content of the granules is about 3%, and granulate;

[0056] f) Add 25% low-substituted hydroxypropyl cellulose to e), and mix well;

[0057] g) adding micropowder silica gel and magnesium stearate to f), and mixing uniformly;

[0058] h) Compressing the obtained g) into tablets.

Embodiment 3

[0060]

[0061] Preparation:

[0062] a) uniformly mix pimobendan and anhydrous citric acid according to the ratio of 1:20, and ultrafinely pulverize them in an ultrafine pulverizer to obtain a micronized mixture with a particle size of 300 mesh;

[0063] b) Other ingredients are passed through a 100-mesh sieve respectively, and set aside;

[0064] c) mix a) with cornstarch, microcrystalline cellulose, 75% low-substituted hydroxypropyl cellulose, and beef powder in equal increments;

[0065]d) adding an aqueous solution of hypromellose to c) to make a soft material;

[0066] e) Perform wet granulation of the prepared soft material, dry at 65°C until the moisture content of the granules is about 3%, and granulate;

[0067] f) Add 25% low-substituted hydroxypropyl cellulose to e), and mix well;

[0068] g) adding micropowder silica gel and magnesium stearate to f), and mixing uniformly;

[0069] h) Compressing the obtained g) into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicinal composition containing pimobendan and a preparation method of the medicinal composition, relating to the field of veterinary drug preparations. The medicinal composition containing pimobendan is composed of pimobendan, a cosolvent, a filler, a disintegrating agent, a corrigent, an adhesive, a lubricant and the like, and the invention further provides the preparation method of the medicinal composition. The medicinal composition is cardiotonic drug, has the strong positive inotropic effect, strong vasorelaxation action and platelet aggregation effect, and is used for treating chronic and acute heart failure. A preparation process is simple, the cost is low, the stability is good, the solubility of pimobendan is increased through the micronization of pimobendan and the cosolvent, and thus the solubility is greatly improved.

Description

technical field [0001] The invention relates to the field of veterinary drug preparations, in particular to a pharmaceutical composition containing pimobendan and a preparation method thereof. Background technique [0002] Drugs for the cardiovascular system mainly act on the heart or vascular system to improve the function of the heart, regulate the total output of blood from the heart, or change the distribution of blood in various parts of the circulatory system. According to the type of disease used for treatment, it is mainly divided into five categories: cardiotonic drugs, antianginal drugs, antiarrhythmic drugs, antihypertensive drugs and blood lipid lowering drugs. Cardiotonic drugs are mainly used to treat various heart failure conditions. Congestive heart failure is a syndrome of cardiac insufficiency caused by various heart diseases. It refers to the absolute or relative insufficient cardiac output due to systolic or diastolic dysfunction under the condition of a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/12A61K31/501A61P9/04
CPCA61K31/501A61K47/12
Inventor 崔亮亮张瑞丽谢龙霄邱梅王苹苹郝智慧
Owner QINGDAO AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap